IIIC期子宫内膜癌辅助化疗与放疗顺序的多中心分析
多中心回顾性队列纳入686例手术分期并接受辅助化疗和放疗的IIIC期子宫内膜癌患者,中位随访45.3个月,5年OS和RFS分别为74%和66%;辅助治疗顺序和类型与OS或RFS无关,单纯近距离治疗与更高的腹主动脉旁淋巴结复发率相关。
要点
- 辅助治疗顺序和类型与OS或RFS无显著相关性。
- 单纯近距离治疗较外照射放疗腹主动脉旁淋巴结复发率更高(15% vs 5%,P<.0001)。
- 远处转移是最常见首次复发部位(20.1%),尽管接受了全身化疗。
核心结论
- 辅助化疗与放疗的顺序和类型不影响IIIC期子宫内膜癌的OS或RFS。
- 单纯近距离治疗与更高的腹主动脉旁淋巴结复发率相关,强调淋巴结放疗的作用。
- 尽管接受全身化疗,绝大多数复发仍为远处转移,提示需要新方案。
研究设计与样本
- 多中心回顾性队列研究,纳入686例手术分期后接受辅助化疗和放疗的IIIC期子宫内膜癌患者。
- 辅助治疗方案分为:先化疗后序贯放疗、同步放化疗后化疗、夹心疗法、先放疗后化疗、化疗同步阴道残端近距离治疗。
- 采用Kaplan-Meier法估计OS和RFS,中位随访45.3个月。
主要发现
- 估计5年OS率为74%,5年RFS率为66%。
- 辅助治疗顺序和类型与OS或RFS无相关性(校正P=.68和.84)。
- 多因素分析显示黑人种族、非子宫内膜样组织学、3级肿瘤、IIIC2期、附件和宫颈受累与更差的OS和RFS相关(均P<.05)。
- 首次复发最常见部位为远处转移(20.1%);阴道仅复发11例(1.6%),盆腔仅复发15例(2.2%),腹主动脉旁淋巴结复发43例(6.3%)。
- 单纯近距离治疗组腹主动脉旁淋巴结复发率为15%,外照射放疗组为5%(P<.0001)。
关键数值与推荐
- 辅助治疗顺序和类型与OS或RFS无相关性(校正P=.68和.84)。
- 黑人种族、非子宫内膜样组织学、3级肿瘤、IIIC2期、附件和宫颈受累与更差的OS和RFS相关(均P<.05)。
- 单纯近距离治疗组腹主动脉旁淋巴结复发率15%,外照射放疗组5%(P<.0001)。
临床怎么用
- IIIC期子宫内膜癌辅助治疗顺序和类型可不影响生存,临床可根据具体情况选择。
- 单纯近距离治疗腹主动脉旁淋巴结复发风险较高,应考虑包含淋巴结放疗的外照射方案。
- 远处转移仍是主要失败模式,需关注新型全身治疗策略。
局限性
- 回顾性研究设计可能存在选择偏倚和混杂因素。
- 原文未报告各治疗组的具体样本量及详细分组数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to evaluate the effect of sequence and type of adjuvant therapy for patients with stage IIIC endometrial carcinoma (EC) on outcomes. METHODS AND MATERIALS: In a multi-institutional retrospective cohort study, patients with stage IIIC EC who had surgical staging and received both adjuvant chemotherapy and radiation therapy (RT) were included. Adjuvant treatment regimens were classified as adjuvant chemotherapy followed by sequential RT (upfront chemo), which was predominant sequence; RT with concurrent chemotherapy followed by chemotherapy (concurrent); systemic chemotherapy before and after RT (sandwich); adjuvant RT followed by chemotherapy (upfront RT); or chemotherapy concurrent with vaginal cuff brachytherapy alone (chemo-brachy). Overall survival (OS) and recurrence-free survival (RFS) rates were estimated by the Kaplan-Meier method. RESULTS: A total of 686 eligible patients were included with a median follow-up of 45.3 months. The estimated 5-year OS and RFS rates were 74% and 66%, respectively. The sequence and type of adjuvant therapy were not correlated with OS or RFS (adjusted P = .68 and .84, respectively). On multivariate analysis, black race, nonendometrioid histology, grade 3 tumor, stage IIIC2, and presence of adnexal and cervical involvement were associated with worse OS and RFS (all P < .05). Regardless of the sequence of treatment, the most common site of first recurrence was distant metastasis (20.1%). Vaginal only, pelvic only, and paraortic lymph node (PALN) recurrences occurred in 11 (1.6%),15 (2.2 %), and 43 (6.3 %) patients, respectively. Brachytherapy alone was associated with a higher rate of PALN recurrence (15%) compared with external beam radiation therapy (5%) P < .0001. CONCLUSIONS: The sequence and type of combined adjuvant therapy did not affect OS or RFS rates. Brachytherapy alone was associated with a higher rate of PALN recurrence, emphasizing the role of nodal radiation for stage IIIC EC. The vast proportion of recurrences were distant despite systemic chemotherapy, highlighting the need for novel regimens.
引用
- Hathout L, Wang Y, Wang Q, et al. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 33677053. doi:10.1016/j.ijrobp.2021.02.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。